SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
SELLAS Life Sciences (SLS) shares fell about 3% on Friday after lab tests of its experimental drug SLS009 in dish-grown pancreatic tumors showed strong cell-killing but answered neither question the stock is priced on.The stock is still down more than 10% this month and well below its June high nea…